Coverage
-
August 09, 2013
Lupin Ltd. and Hi-Tech Pharmacal Corp. infringed a patent relating to Allergan Inc.'s pinkeye treatments Zymaxid through their proposed generic versions of the antibiotics, but the asserted claims in the patent are invalid because of obviousness, a Delaware federal judge ruled Friday.
1 other articles on this case.
View all »